Obstacles for independent transnational clinical trials in Europe

International Journal of Pharmaceutical Medicine

Volumn 12, Issue 3, 1998, Pages 133-136

  Lacombe, D ^a   Therasse, P ^a   Meunier, F ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Cancer; Clinical trials; Ethical review; Independent research bodies; Insurance and indemnity

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG INDUSTRY; EUROPE; GOOD CLINICAL PRACTICE; HEALTH CARE POLICY; HUMAN; INSURANCE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; SURVIVAL;

EID: 0031817874     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Verweij J, Mouridsen HT, Nielssen OS, Woll PJ, van Oosterom AT, Van Glabbeke M et al. The present state-of-the-art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Clin Rev Onc/Hem 1995; 20:193-201.
2. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organisation for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88:890-898.
3. Van der Burg MEL, Van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G et al. The Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. New Engl J Med 1995; 332:629-634.
4. Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Sponer D, Bramwel VHC et al. Randomised trial of two regimens in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350:911-917.
5. Guest S. Compensation for subjects of medical research: the moral rights of patients and the power of research ethics committees. J Med Ethics 1997; 23:181-185.
6. Smitt SR. Insurance coverage for clinical investigation. The Pharos 1991; 34.
7. de Bouyalski I, Lacombe D. The development of the guidelines and recommendations for European ethics committees by the European Forum for Good Clinical Practice. Int J Pharm Med 1997;11:125-127.